As announced in October 2017, Animas Corporation is exiting the insulin pump business and intends to discontinue the manufacturing and sale of Animas® Vibe® insulin pumps, including in the United Kingdom. This decision was extremely difficult and comes following an extensive exploration of all viable other options for the Animas business. Animas' goal is to transition all patients globally to another insulin delivery system and exit the market by September 2019.

In February 2018, the Competition and Markets Authority (CMA) initiated a review of Animas' transition plan in the United Kingdom and in particular, arrangements Animas had made with Medtronic as its preferred partner to facilitate patient transition and ensure continuity of care as Animas exits the market. As is standard in reviews of this kind, the CMA has imposed an order on Medtronic and Animas, prohibiting either from taking any steps to have Medtronic on-board patients who wish to switch in line with the process set out in our letter of 29 January 2018, until the CMA has further progressed its review.

We recognise that patients living with diabetes rely on our products to provide critical care, and we want to reassure patients and their care teams that we will be there, every step of the way, throughout this process. Patient safety and continuity of care is of utmost importance to Animas. To ensure this order does not affect continuity of care, Animas will continue to serve all customers on a business as usual basis, until such time as the order is lifted. If you are currently using an Animas pump and pump supplies, you will continue to receive pump support and services. Specifically, Animas will continue to provide customer service and warranty support, including providing pump supplies that are used in conjunction with the Animas® Vibe® insulin pumps, through a transition period. As part of our continued commitment to patient care, Animas will honour pump warranties.

Our number one priority remains ensuring that patients have a seamless experience and continuity of care. If you would like to discuss any element of this letter, please contact the Animas team at;

Johnson & Johnson Diabetes Care Companies,
Johnson & Johnson,
50-100 Holmers Farm Way,
High Wycombe,
HP12 4DP.

Animas® Customer Service: 0800 055 6606 (UK). Animasuk@its.jnj.com.